Literature DB >> 32130727

Inoculum size and traits of the infecting clinical strain define the protection level against Mycobacterium tuberculosis infection in a rabbit model.

Liana Tsenova1,2, Dorothy Fallows1,3, Afsal Kolloli1, Pooja Singh1, Paul O'Brien1,4, Nicole Kushner1,5, Gilla Kaplan1,6, Selvakumar Subbian1.   

Abstract

Host protective immunity against pathogenic Mycobacterium tuberculosis (Mtb) infection is variable and poorly understood. Both prior Mtb infection and BCG vaccination have been reported to confer some protection against subsequent infection and/or disease. However, the immune correlates of host protection with or without BCG vaccination remain poorly understood. Similarly, the host response to concomitant infection with mixed Mtb strains is unclear. In this study, we used the rabbit model to examine the host response to various infectious doses of virulent Mtb HN878 with and without prior BCG vaccination, as well as simultaneous infection with a mixture of two Mtb clinical isolates HN878 and CDC1551. We demonstrate that both the ability of host immunity to control pulmonary Mtb infection and the protective efficacy of BCG vaccination against the progression of Mtb infection to disease is dependent on the infectious inoculum. The host response to infection with mixed Mtb strains mirrors the differential responses seen during infection with each of the strains alone. The protective response mounted against a hyperimmunogenic Mtb strain has a limited impact on the control of disease caused by a hypervirulent strain. This preclinical study will aid in predicting the success of any vaccination strategy and in optimizing TB vaccines.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  BCG; Mixed infection; Protective immunity; Pulmonary tuberculosis; Rabbit model

Mesh:

Substances:

Year:  2020        PMID: 32130727     DOI: 10.1002/eji.201948448

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model.

Authors:  Abrianna Beever; Nala Kachour; James Owens; Kayvan Sasaninia; Afsal Kolloli; Ranjeet Kumar; Santhamani Ramasamy; Christina Sisliyan; Wael Khamas; Selvakumar Subbian; Vishwanath Venketaraman
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

2.  Liposomal Glutathione Helps to Mitigate Mycobacterium tuberculosis Infection in the Lungs.

Authors:  Nala Kachour; Abrianna Beever; James Owens; Ruoqiong Cao; Afsal Kolloli; Ranjeet Kumar; Kayvan Sasaninia; Charles Vaughn; Mohkam Singh; Edward Truong; Christopher Khatchadourian; Christina Sisliyan; Klara Zakery; Wael Khamas; Selvakumar Subbian; Vishwanath Venketaraman
Journal:  Antioxidants (Basel)       Date:  2022-03-30

Review 3.  One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics.

Authors:  Hee-Jeong Yang; Decheng Wang; Xin Wen; Danielle M Weiner; Laura E Via
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

4.  Aggregation state of Mycobacterium tuberculosis impacts host immunity and augments pulmonary disease pathology.

Authors:  Afsal Kolloli; Ranjeet Kumar; Pooja Singh; Anshika Narang; Gilla Kaplan; Alex Sigal; Selvakumar Subbian
Journal:  Commun Biol       Date:  2021-11-03

5.  Effects of Glutathione Diminishment on the Immune Responses against Mycobacterium tuberculosis Infection.

Authors:  Ruoqiong Cao; Afsal Kolloli; Ranjeet Kumar; James Owens; Kayvan Sasaninia; Charles Vaughn; Mohkam Singh; Edward Truong; Nala Kachour; Abrianna Beever; Wael Khamas; Selvakumar Subbian; Vishwanath Venketaraman
Journal:  Appl Sci (Basel)       Date:  2021-09-06       Impact factor: 2.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.